Since the introduction of the concept of precision medicine in 2015, scientists engaged in biomedical research around the world are looking for newer and more accurate technologies to accurately classify tumors in order to find the most accurate drugs to achieve precise treatment of tumors and to break through cancer treatment. bottleneck.

In October 2016, Nature, the world's top magazine, published an article, using NanoSi1000, the company's ProteinSimple, as a technology platform to develop new strategies for tumor typing diagnosis and to guide the precise treatment of tumors.

The authors come from the world's largest private cancer research center: the Sloan-Kettering Cancer Institute, and the world-renowned medical research institutions such as Cornell University School of Medicine.

The researchers found that the formation of large protein complexes is highly correlated with tumor survival and tumor sensitivity to therapeutic drugs. The sample was obtained from patients with acute myeloid leukemia. The author used HSP90 as a research target protein and used Nanopro1000 as a research platform to study whether the patient's body would form an HSP90 protein complex. The normal HSP90 isoelectric point is 4.9. If the formed HSP90 protein complex has an isoelectric point greater than 4.9 and is named "type I" tumor, the HSP90 protein complex has an isoelectric point of less than 4.9, which is named "type 2" tumor. The study found that "type 1" tumors are sensitive to HSP90 inhibitor therapy, and "type 2" tumors are not sensitive to HSP90 inhibitors, so other treatments need to be selected.

Original reading:

HSP90 focused primary as a single species at the predicted isoelectric point (pI) of 4.9. However, cancer cell lines analysed by this method contained a complex mixture of HSP90 species spanning a pI range of 4.5 to 6; HSP90α and HSP90β isoforms were part of These complexes. further, although all cancer cell lines contained a number of HSP90 complexes with pI < 4.9, a subset was enriched in HSP90 complexes with the unusual pI of ≥5, herein referred to as 'type 1' cells. We refer to cancer Cell lines that contained mainly complexes with pI < 4.9 as 'type 2' cells.

Nanopro1000 ultra-sensitive protein immunoassay system can directly use micro-clinical puncture samples from patients, perform isoelectric focusing separation and immunoassay of protein natural structure, and map changes in patient protein structure, post-translational modification, amino acid mutation, etc. . According to changes in protein profiles, disease-related diagnostic maps are drawn and precision-guided treatments are developed. Molecular typing standards for diagnosis of leukemia, lymphoma, and fatty liver have been published in many leading journals such as Nature, Nature Medicine, Cell Stem cell, etc., which have brought new strategies for re-recognizing diseases, accurate diagnosis, and precise treatment. Original reading:

To identify and separate chaperome complexes in tumours, and to overcome the limitations of classical protein chromatography methods for resolving complexes of similar composition and size, we took advantage of a capillary-based platform that combines isoelectric focusing (IEF) with immunoblotting capabilities. The method uses only minute amounts of sample, thus enabling the interrogation of primary specimens.

For more information, please visit:

Monkfish Series

Monkfish-Sliced,Monkfish-Fillets,Monkfish Tails With Skinless,Monkfish Tails With Skin-On

GOLD STAR FISHERY ZHOUSHAN CO.,LTD. , https://www.goldstar-aquatic.com